Income Statement Presentation 2023

2022: Pharma and Diagnostics underlying business driving growth CHFM 62'801 +2% at CER Diversification of Roche business +273 +903 +3'356 -801 -1,883 2017 CHF 53.3bn -457 -911 Total COVID-19 sales decline equals roughly 1bn 63'281 AHR Diagnostics Other pharma Ophthalmology 2022 CHF 63.3bn AHR Oncology Immunology Neuroscience 2021 Dia Dia Pharma Ronapreve Actemra base COVID-19 excl. sales business sales Ronapreve, Actemra, AHR sales AHR erosion1 Fx 2022 Infectious diseases Hemophilia A 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion Roche 51

View entire presentation